Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | SOD3 | P08294 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210516 | 0.98 | SOS1 (0.39) | SOS1SOS2GNAO1GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL6291188 | 0.95 | GNAO1 (0.40) | SOS1SOS2GNAO1GNAI3GNAI1 | |
| SCHEMBL28210463 | 0.94 | SOS1 (0.41) | SOS1SOS2GNAO1GNAI3GNAI1 | |
| SCHEMBL27911334 | 0.93 | SOS1 (0.38) | SOS1SOS2GNAO1GNAI3GNAI1 | |
| SCHEMBL9236814 | 0.82 | GNAO1 (0.34) | SOS1SOS2GNAO1GNAI3GNAI1 | |
| SCHEMBL4893037 | 0.80 | GNAI3 (0.35) | GNAO1GNAI3GNAI1 | |
| SCHEMBL7029095 | 0.80 | GNAO1 (0.39) | GNAO1GNAI3GNAI1 | |
| SCHEMBL28142685 | 0.78 | SOS1 (0.47) | SOS1SOS2 | |
| SCHEMBL28210448 | 0.77 | GNAI3 (0.34) | GNAO1GNAI3GNAI1 | |
| SCHEMBL7025040 | 0.76 | GNAI3 (0.33) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | claimed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | claimed |
| US-9701645-B2 | Method of treating Parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2017-07-11 | — | — | US | claimed |
| CN-105198788-A | Indole oxoacetyl (N-diaryl methyl) piperazine derivatives and preparation method and application thereof | JIANG JUNRONG | 2015-12-30 | — | — | CN | claimed |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | VERSI GROUP, LLC (US) | 2014-10-23 | — | — | US | claimed |
| US-8642599-B2 | Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity | VERSI GROUP, LLC (US) | 2014-02-04 | — | — | US | claimed |
| EP-1450807-B1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-12-25 | — | — | EP | claimed |
| US-20100221200-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | claimed |
| WO-2009012376-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-01-22 | — | — | WO | claimed |
| EP-1450807-A4 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | EP | claimed |
| US-20060004016-A1 | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent | DMK PHARMACEUTICALS CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | claimed |
| US-20040171622-A1 | Cardioprotective delta opioid receptor agonists and methods of using same | DMK PHARMACEUTICALS CORPORATION | 2004-09-02 | — | — | US | claimed |
| EP-1450807-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003057313-A1 | METHOD FOR SCREENING THERAPEUTIC AGENTS FOR MODULATION OF EJACULATORY RESPONSE | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20030130698-A1 | Method for screening therapeutic agents for modulation of ejaculatory response | ENTA HOLDING LLC | 2003-07-10 | — | — | US | claimed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-20020111359-A1 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | US | claimed |
| US-20020052007-A1 | Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives | ENTA HOLDING LLC | 2002-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111359-A1 | Side effect reduction of narcotics | OPRD1, OPRM1, OPRK1 | SOS1 4550/4885SOS2 4435/4885GNAO1 389/4885 |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | SOS1 3432/4885SOS2 3135/4885GNAO1 428/4885 |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | SOS1 3748/4885SOS2 3071/4885GNAO1 281/4885 |
| US-20040171622-A1 | Cardioprotective delta opioid receptor agonists and methods of using same | OPRD1, OPRK1, OPRM1 | SOS1 2870/4885SOS2 3054/4885GNAO1 1174/4885 |
| US-20060004016-A1 | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent | OPRM1, OPRK1, OPRD1 | SOS1 3018/4885SOS2 2238/4885GNAO1 957/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | SOS1 3748/4885SOS2 3071/4885GNAO1 281/4885 |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | SOS1 3748/4885SOS2 3071/4885GNAO1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.